Novo Nordisk, CagriSema and Drug Trial
Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations
CagriSema produced an average 15.7% weight reduction in overweight or obese individuals with type 2 diabetes, according to the research results. Weight reduction under the trial product estimand (if all adhered to treatment) was 15.
Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...
The trial of CagriSema in patients who were obese or overweight and with type 2 diabetes failed to show a clear superiority to a drug from rival Eli Lilly, analysts said. The CagriSema group had ...
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback